Literature DB >> 16717055

In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).

Flávia Rossi1, Fernando Baquero, Po-Ren Hsueh, David L Paterson, Grant V Bochicchio, Theresa A Snyder, Vilas Satishchandran, Kathleen McCarroll, Mark J DiNubile, Joseph W Chow.   

Abstract

OBJECTIVES: SMART (Study for Monitoring Antimicrobial Resistance Trends) is an ongoing study to monitor worldwide antimicrobial resistance trends among aerobic and facultatively anaerobic Gram-negative bacilli (GNB) isolated from intra-abdominal infections. This 2004 report summarizes the most recently completed annual data from SMART.
METHODS: During 2004, 81 medical centres from 28 countries in five global regions collected intra-abdominal GNB for antimicrobial susceptibility testing using broth microdilution according to the Clinical and Laboratory Standards Institute guidelines.
RESULTS: A total of 6156 unique aerobic and facultatively anaerobic GNB were isolated from intra-abdominal infections. Enterobacteriaceae composed 86% of the total isolates. Among the 12 antimicrobial agents tested, the carbapenems and amikacin were the most consistently active against the Enterobacteriaceae. Escherichia coli was the most commonly isolated species (48%), and the susceptibility rate to the quinolones was lowest in Asia/Pacific and Latin America. Extended-spectrum beta-lactamases (ESBLs) were detected phenotypically in 10% of E. coli, 17% of Klebsiella spp. and 22% of Enterobacter spp. worldwide, representing a slight increase over the two previous years. ESBL producers typically had a more antibiotic-resistant profile than non-ESBL producers but were usually susceptible to the carbapenems.
CONCLUSIONS: Antimicrobial resistance among GNB isolated from intra-abdominal infections continued to be a problem worldwide in 2004, with the highest rates of resistance overall in the Asia/Pacific region. The carbapenems and amikacin were the most consistently active agents in vitro against Enterobacteriaceae isolated from intra-abdominal infections worldwide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16717055     DOI: 10.1093/jac/dkl199

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  40 in total

1.  Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).

Authors:  Daryl J Hoban; Samuel K Bouchillon; Stephen P Hawser; Robert E Badal; Vincent J Labombardi; Joseph DiPersio
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Antimicrobial stewardship.

Authors:  Shira Doron; Lisa E Davidson
Journal:  Mayo Clin Proc       Date:  2011-11       Impact factor: 7.616

Review 3.  [Antimicrobial and antimycotic therapy of intra-abdominal infections].

Authors:  P Kujath; M Hoffmann; A Rodloff
Journal:  Chirurg       Date:  2008-04       Impact factor: 0.955

Review 4.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

5.  Canadian practice guidelines for surgical intra-abdominal infections.

Authors:  Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 6.  Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Authors:  Souha S Kanj; Zeina A Kanafani
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

7.  Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.

Authors:  F Docobo-Pérez; L López-Cerero; R López-Rojas; P Egea; J Domínguez-Herrera; J Rodríguez-Baño; A Pascual; J Pachón
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

8.  High rate of intestinal colonization with extended-spectrum-beta-lactamase-producing organisms in household contacts of infected community patients.

Authors:  Aránzazu Valverde; Fabio Grill; Teresa M Coque; Vicente Pintado; Fernando Baquero; Rafael Cantón; Javier Cobo
Journal:  J Clin Microbiol       Date:  2008-06-18       Impact factor: 5.948

9.  A focus on intra-abdominal infections.

Authors:  Massimo Sartelli
Journal:  World J Emerg Surg       Date:  2010-03-19       Impact factor: 5.469

10.  Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis.

Authors:  Pascal Augustin; Nathalie Kermarrec; Claudette Muller-Serieys; Sigismond Lasocki; Denis Chosidow; Jean-Pierre Marmuse; Nadia Valin; Jean-Marie Desmonts; Philippe Montravers
Journal:  Crit Care       Date:  2010-02-15       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.